ANI acquires 22 previously marketed generic drug items for $25 million from Teva Pharmaceuticals ANI Pharmaceuticals, Inc colofac retard . today announced that it has acquired 22 previously marketed generic drug items from Teva Pharmaceuticals for $25 million in cash and a share of future gross earnings from product sales. The acquisition includes 19 solid-oral dosage products, and 3 oral suspension products. ANI will in the beginning focus to tech transfer four products that qualify as CBE30 filings into ANI's two manufacturing facilities; these four products have a combined trailing twelve month marketplace value of $210 million, regarding to IMS Health.
AMP raises ethical, laboratory practice issues in whole genome sequencing at SACHGS meeting Today, the Association for Molecular Pathology presented public comments to the Secretary’s Advisory Committee on Genetics, Health insurance and Society conference focused on entire genome sequencing. In anticipation of improvements in sequencing and its incorporation into medical practice, AMP elevated ethical and laboratory practice worries for the Committee’s factor. ‘In the next five years, the use of whole genome sequencing methods in the laboratory and subsequently the clinic is a very real possibility,’ stated Dr.